Association between periodontitis and systemic medication intake: A case-  control study by Wang, I‐ching et al.
 
 
This is the author manuscript accepted for publication and has undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/JPER.19-0593. 
This article is protecte.d by copyright. All rights reserved. 
<PE-AT>Association Between Periodontitis and Systemic Medications intake:  
A Case-control Study 
I-Ching Wang, DDS*, Houssam Askar, BDS*, Iya Ghassib, DDS*, Chin-Wei Wang, DDS, 
DMSc*, and Hom-Lay Wang, DDS, MSD, PhD* 
* Department of Oral Medicine and Periodontics, University of Michigan, Ann Arbor, MI, USA 
Corresponding Author 
Hom-Lay Wang, DDS, MSD, PhD 
Department of Periodontics and Oral Medicine.  
University of Michigan, School of Dentistry 
1011 North University Avenue 
Ann Arbor, MI. 48109-1078 
Phone: +1-734-763-3383 
Fax: +1-734-936-0374 
e-mail: homlay@umich.edu  
Word Count: 3896 
Numbers of figures: 2 
Numbers of tables: 3 (supplemental 2) 
Numbers of references: 55 
Short Running Title: Association Between Periodontitis and Systemic Medications 
 
 
This article is protected by copyright. All rights reserved. 
One-Sentence Summary: Patients with periodontitis exhibited significantly higher 
medication intake frequency related to cardiovascular disease and diabetes with a potential 
disease severity-dependent association.  






To investigate the frequency of systemic drugs taken by elderly patients with or without 
periodontitis and the possible association between medication consumption and the severity 
of periodontitis.  
Methods: 
A total of 1221 patients, including 608 with generalized moderate to severe periodontitis 
(periodontitis group) and 613 age- and gender-matched individuals with healthy 
periodontium (healthy group) were selected.  Systemic conditions, medications and 
periodontal status were recorded. Medication intake frequency (%) was compared using 
unconditional logistic regression.  
Results: 
The top three most common medications were angiotensin-converting enzyme (ACE) 
inhibitors (17.9%), antidepressants (17.8%), and lipid-lowering medications (16.5%). Both 
ACE inhibitors and antidepressants showed statistically higher intake frequency in the 
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periodontitis group relative to healthy controls (21.5 vs. 14.4%; odds ratio (OR) = 1.64), (21.1 
vs. 14.5%, OR=1.57) (p<0.01). Additionally, intake of oral hypoglycemic agents, calcium 
channel blockers, insulin and diuretics were significantly higher in the periodontitis group 
with OR= 2.49, 2.32, 2.08 and 1.79, respectively (p<0.05). Several medications 
demonstrated a disease severity-dependent association comparing generalized severe 
periodontitis with moderate periodontitis and healthy group: oral hypoglycemic agents (17.4 
vs. 16.8 vs. 8.0%), calcium channel blockers (14.8 vs. 14.4 vs. 8.0%) and anticonvulsants 
(13.4 vs. 7.7 vs. 6.4%) with OR of 2.43, 1.99, and 2.28 (severe periodontitis vs. healthy 
group), respectively.  
Conclusion: 
There was a significantly higher frequency of medication intake related to cardiovascular 
disease and diabetes in patients with periodontitis.  A disease severity-dependence with 
medication intake frequency was also noted. This study provides indirect evidence for the 
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INTRODUCTION 
The association between systemic diseases and periodontitis has been widely investigated1. 
In the past 20 years, a diversity of 57 systemic conditions have been hypothesized to be 
linked with periodontal disease2. The evolving knowledge of the role of chronic inflammation 
in systemic diseases, such as cardiovascular diseases3, diabetes mellitus (DM)4, rheumatoid 
arthritis5, metabolic syndrome6, Alzheimer’s disease7, cancer8, 9, and other inflammatory 
diseases contributes to the understanding of potential biological pathways linking periodontal 
disease with systemic inflammation. Constantly , they were described as multifactorial 
diseases in the presence of multiple comorbidities, and concurrently shared multiple risk 
factors with periodontal disease10. Plausible biologic mechanisms underpinning the link 
between periodontitis and systemic diseases include metastatic infection, systemic spread of 
inflammatory mediators, activation of adaptive immunity, and elevated total burden of 
systemic inflammation11. Medication intake frequency may directly reflect systemic disease 
severity and can indirectly represent the systemic inflammatory burden in chronic 
inflammatory diseases. However, little is known regarding the systemic medications taken by 
patients with chronic periodontitis, especially in elderly populations.  
Currently, there is limited information regarding the medication profile in patients with 
periodontitis and whether there is a difference compared with individuals with a healthy 
periodontal status. Hence, the aim of this study was to investigate the frequency and types 
of systemic medications taken by elderly patients with or without periodontitis and the 
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MATERIALS AND METHODS 
Study design  
This case-control retrospective study was approved with exemption for informed consent by 
the Institutional Review Board of the University of Michigan (IRB protocol # HUM00147292) 
and was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2013. 
Furthermore, all patient data and charts were anonymized since the data were retrieved 
without any identifiable information. The present age- and gender-matched case-control 
study was designed to assess whether periodontitis is associated with the intake of systemic 
drugs. In order to increase the detection power of systemic inflammatory burden, “cases” 
were selected based on diagnosis with generalized moderate to severe periodontitis on the 
basis of exhibiting pocket depth  5 mm in more than 30% teeth without previous history of 
periodontal treatment. The randomly selected “controls” represented periodontally healthy 
individuals with a 1:1 ratio between cases and controls. A power calculation was performed 
under the expectation of a crude odds ratio of 2 with power of 85%. It was assumed that 5% 
of controls were exposed to the medication consumption in general with an alpha risk of 5%. 
The estimated sample size was 1146 (573 matched pairs). The final sample size of 1200 
(600 matched pairs ) was determined to increase the power of detection.  
Patient screening and sample selection  
The electronic health records (EHRs) of patients seen in the Graduate Periodontics Clinic, 
School of Dentistry, University of Michigan between 2012 and February 2018 were screened 
by electronic search of American Dental Association (ADA) codes in the EHR software† to 
identify the cohort with periodontitis who had received scaling/root planing treatment. Three 
investigators (ICW, HA, IG) performed screening through periodontal charts at the initial 
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examination to document the number of remaining teeth, and the number of teeth with 
pocket depth (PD) ≤ 4 mm, >4 to <7 mm and ≥ 7 mm.  
Case Definition of Periodontitis  
According to the 2015 Update to the 1999 Classification of Periodontitis12, generalized 
moderate periodontitis was defined as more than 30% of remaining teeth with PD ≥ 5 mm 
and < 7 mm. Severe periodontitis was identified as PD ≥ 7 mm with extent being defined as 
either localized (involvement of ≤ 30% of remining teeth) or generalized (> 30% of remaining 
teeth). Only the disease severity more than generalized moderate or severe periodontitis 
patients at the initial examination were included in the “case” group.  
After the characteristics (age/gender) of periodontitis group were established, the control 
cohort was constructed accordingly by randomly selecting periodontally healthy individuals 
who had a history of periodontal examination in the EHR system. Periodontal status was 
confirmed by comprehensive examination of the initial periodontal chart.  
Inclusion criteria 
1. A minimum age of 40 years old 
2. Patients with diagnosis of generalized moderate to severe chronic periodontitis at the 
baseline examination were included in the “case” group 
3. Individuals with healthy periodontal condition to mild periodontitis (PD of all teeth ≤ 4 
mm) were included in the “control” group 
4. Adequately completed health history questionnaire was available in the EHR 
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Exclusion criteria 
1. Patients had periodontal treatment within 1 year of initial examination at the 
University of Michigan  
2. Age < 40 years old 
Data Extraction 
Data was extracted from the EHRs by three investigators (ICW, HA, IG) including 
demographic information (age, gender) and self-reported history of systemic diseases 
including cardiovascular diseases, hypertension, diabetes, other endocrine disorders, 
metabolic symptoms, rheumatoid disease, allergy, depression, Alzheimer’s disease or other 
psychogenic disorders, cancer, and other systemic conditions. Oral intake of systemic 
medications taken over more than three months was recorded including types of medication, 
purpose of intake, and history of use. International nonproprietary names (INN), also known 
as generic names, were used in the descriptive analysis to allow precise identification and 
communication. Certain systemic medications including antibiotics, corticosteroids, and non-
steroid anti-inflammatory drugs as well as non-oral routes of administration or intake history 
less than 3 months were excluded from the analysis. 
Statistical analysis 
Continuous variables were presented with absolute number (n), mean and standard 
deviation (SD). Two groups were compared using the Wilcoxon signed rank test after a 
normality test. Medication consumptions were converted in percentages as the intake 
frequencies (%) among groups and analyzed using unconditional logistic regression. 
Univariate logistic regression was performed to detect the significant differences of all the 
possible confounding covariates, including age, gender and number of remaining teeth. 
Significant covariates were adopted in the multivariable logistic regression model, and 
categorical covariates with predetermined cut-off points (such as every 10-year increase of 
 
 
This article is protected by copyright. All rights reserved. 
age, and remaining teeth number ≥ 20 or < 20 teeth) were combined to facilitate 
interpretation. Odds ratio (OR) represents the relative intake frequency in the periodontitis 
group relative to the control group. OR>1 indicates the intake frequency was higher in the 
periodontitis group compared to the control group. Stratified analysis according to the 
disease severity and extent was performed using a chi-square test to evaluate the 
association between periodontitis severity and medication frequency and number of types. 
The association between the number of remaining teeth, the amount and the types of 
systemic medications and the disease severity were analyzed using Pearson chi-square 
test. P-value < 0.05 was considered as statistically significant. All statistical analysis was 
performed by using a software package‡. 
 
RESULTS 
The demographics of the study participants were presented in Table 1. The demographic 
characteristics, including age and gender distribution, were similar between the “case” 
periodontitis and “control” healthy groups (female 37%/male 63% in both groups; mean age 
of 61.8 versus 59.8 years (periodontitis versus healthy)). 
A total of 33 kinds of medications for treatment of 12  categories of systemic diseases or 
conditions were documented, including diabetes mellitus, cardiovascular diseases, thyroid 
disorder, gastrointestinal conditions, respiratory diseases, osteoporosis or bone-related 
disorder, immune condition, prostate hyperplasia, genitourinary disorder, muscle-skeletal 
condition, gout and neurologic disorders. The most frequent medication types and 
prevalence of consumption in both the periodontitis and health groups were shown in Table 
2. The three most common medications found in both groups were ACE inhibitors for 
cardiovascular diseases (17.9%), antidepressants (17.8%) and lipid-lowering medication 
(16.5%). Both ACE inhibitors and antidepressants showed statistically significantly (P<0.01) 
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higher intake frequency in the periodontitis group relative to the healthy group (21.5% vs. 
14.4%; OR=1.64; 21.1% vs. 14.5%, OR=1.57, respectively). In contrast, the lipid-lowering 
agents showed less prevalence (26.1% vs 6.7%; OR=0.21) in periodontitis group. The 
complete information of the frequencies of all systemic medications collected in the current 
investigation were presented in supplemental Table 1 (see Supplemental Table 1 in online 
Journal of Periodontology). 
 
Significant difference between periodontitis and healthy groups 
In the results of unconditional logistic regression, only 12 kinds of medications showed 
significant differences between periodontitis and healthy groups. They were presented in 
Table 3 and illustrated below. Figure 1 demonstrated these 12 drugs in the ranking of intake 
prevalence among the periodontitis group. Three medications displayed a disease severity-
dependent association with the intake frequency, including  oral hypoglycemics, calcium 
channel blockers, and anticonvulsants (Figure 2). Significant results in the subgroup analysis 
of the generalized severe periodontitis (GSP) group under the multiple logistic regression 
model were reported in supplemental Table 2 (see Supplemental Table 2 in online Journal of 
Periodontology). 
 
A statistically significant negative correlation was found between the number of remaining 
teeth and the severity of periodontal disease (R= -0.35, p< 0.01). No significant difference 
between the amount of medication consumption between groups (p=0.12) or different 
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Medications for Cardiovascular Diseases  
Angiotensin-converting enzyme (ACE) inhibitors 
ACE inhibitors were found to be the most common medication taken in general and 
specifically within the periodontitis group. The prevalence of ACE inhibitor usage was 
significantly higher in the periodontitis group (21.5%) compared to the control group (14.4%) 
(OR= 1.64, p= 0.001). However, after adjusting for age, gender and number of remaining 
teeth, the positive association didn’t reach the threshold of significance with an adjusted OR 
(aOR)=1.26 (p=0.19).  
Calcium channel blockers 
Calcium channel blockers were found more commonly in patients with periodontitis (16.8%) 
than healthy controls (8.0%) with OR= 2.32 (p< 0.001). After adjusting for age, gender and 
number of remaining teeth, those who consumed calcium channel blockers had higher odds 
of developing periodontitis (adjusted OR= 2.09, p<0.001). Compared to healthy controls, the 
frequency of intake was significantly higher in the generalized moderate periodontitis group 
(14.4%, OR= 1.94, p=0.01) and even higher in GSP group (14.8%, OR= 1.99, p=0.01) with 
aOR= 2.1 (p=0.03), which implied a severity-dependent association.  
Diuretics 
Diuretics including thiazide (hydrochlorothiazide, HCTZ) or thiazide-like (chlortalodone) 
diuretics, loop diuretics (furosemide), and potassium-sparing diuretics (such as 
spironolactone, triamterene) were recorded in this study. Taken together, the prevalence of 
diuretic intake in periodontitis group was 15.0%, which was significantly higher than the 
healthy group (9.0%) with OR= 1.79 (p=0.001). Higher intake frequency of diuretics was 
significantly associated with periodontitis, independent of age, gender and the remaining 
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number of teeth (adjusted OR= 1.6, p=0.02). The difference between the GSP and control 
groups reached borderline significance (p=0.07) with an OR of 1.66.  
Anti-coagulants 
Two categories including anti-coagulants (heparin, warfarin, rivaroxaban, apixaban and 
dabigatran) and antiplatelet drugs (aspirin, clopidogrel, ticagrelor) were documented in the 
current investigation. It was found that healthy individuals took blood-thinners more often 
than the periodontitis group (21.0% vs. 11.7%, OR= 0.5, p< 0.001). After adjusting for the 
possible confounders, the adjusted OR was 0.41 (p< 0.001). However, when the prevalence 
in healthy group was compared to the GSP group (15.4%), it was not significant different 
(p=0.14).  
Blood-lipid lowering medications 
Statins (atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and fluvastatin), 
ezetimibe and fibrate were recorded in this category. Significantly lower intake frequency 
was found in the periodontitis group (6.7%) compared to the healthy group (26.1%) with 
OR=0.21 (p<0.001). The intake of lipid-lowering medications was associated with an 87% 
reduction in the odds of periodontitis (adjusted OR= 0.13, p< 0.001) after adjusting for age, 
gender, and the number of remaining teeth. This significant difference remained when 
comparing the GSP group (9.4%) with the healthy group (OR=0.29, p<0.001).  
Alpha2-agonists 
 
The consumption of alpha2-agonists had a higher prevalence in the periodontitis group 
(1.48%) compared to the control group (0.33%) with OR=4.59 (p=0.03). After adjusting for 
age, gender and number of remaining teeth, the difference didn’t reach significance 
 
 
This article is protected by copyright. All rights reserved. 
(adjusted OR=3.38, p=0.14). Similarly, the difference between the GSP group (0.67%) and 
control was insignificant (p=0.48).  
Medications for Neurologic Disorders 
Antidepressants 
Antidepressant consumption was reported by 21.1% of the periodontitis group, and it was 
associated with a 57% increase of odds compared to the healthy group (14.5%, p= 0.003). 
After adjusting for age, gender, and number of remaining teeth, the adjusted OR was 1.48 
(p=0.03). Those who consumed antidepressants demonstrated higher odds of generalized 
moderate periodontitis (26.0%, OR= 2.1, p< 0.001). Although the frequency of intake was 
18.8% in the GSP group, there was a non-significant difference compared to the control 
group (OR=1.36, p= 0.21).  
Anticonvulsant 
It was shown that patients in the periodontitis group had a higher chance of taking 
anticonvulsants (9.5%) compared to the healthy group (6.4%) with a crude odds ratio 1.55 
(p=0.04). After the adjustment of age, gender and number of remaining teeth, the adjusted 
odds ratio was statistically insignificant (aOR=1.6, p=0.12). Nevertheless, a severity-
dependent association was observed (7.7% in GMP group; 13.4% in GSP group) with 
OR=2.28, p< 0.01 (aOR=2.02, p=0.03) for generalized severe periodontitis.  
 
Antipsychotic Drugs 
Antipsychotic drugs interestingly demonstrated a higher prevalence in the periodontitis group 
(4.4%) with 2 times the odds compared to the healthy control (2.1%) (p=0.03). Independently 
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of age, gender and number of remaining teeth, the adjusted odds ratio was higher as 2.42 
(p=0.02). The frequency of intake was higher in the generalized moderate periodontitis 
group (8.2%) with 4 times higher odds than the healthy group (p< 0.001). A disease 
periodontitis severity-dependent association was not observed in the GSP group (OR= 0.63, 
p=0.75).  
Medications for Diabetes Mellitus  
Insulin 
The intake frequency of insulin was reported as 4.18% of the total population. Patients in the 
periodontitis group had a higher chance of taking insulin (5.59%) compared to the control 
group (2.77%, OR=2.08, p=0.02). Insulin intake was significantly associated with 
periodontitis independently of age, gender and number of remaining teeth (adjusted 
OR=2.13, p= 0.03). However, insulin intake did not reach significance in a comparison 
between the generalized severe periodontitis group (GSP) (5.37%) and the control group 
(OR=1.99, p=0.12).   
Oral hypoglycemic agents 
The total prevalence of use was 12.9%, and it was significantly higher in the periodontitis 
group relative to the healthy control group (17.8% vs. 8.0%, OR=2.49, p< 0.001). The 
percentage of intake was significantly higher in the generalized moderate periodontitis group 
(16.8%, OR= 2.3, p= 0.001) compared to the control group. Moreover, the prevalence was 
highest in the GSP group (17.4%) with an OR of 2.43 compared to the control (p= 0.001) 
(aOR=2.56, p< 0.01), which indicates that frequency of intake of hypoglycemics is directly 
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Medications for Asthma  
Bronchodilators  
The prevalence of intake of bronchodilators for treatment of asthma, including albuterol, 
formoterol, levalbuterol and montelukast, was 2.3% in the periodontitis group compared to 
4.6% in the healthy group. A negative association was found (OR= 0.49, p= 0.03). The 
significance remained in the multivariable logistic regression model (adjusted OR= 0.45, 
p=0.04). In the GSP group, the frequency of intake was 2.7% with no significant difference 
compared to the healthy control group (OR= 0.58, p= 0.37).  
 
DISCUSSION 
To the best of our knowledge this is the first study to investigate the potential association 
between systemic medication consumption and periodontal disease severity. The current 
investigation aimed to evaluate a possible indirect association between systemic diseases 
and periodontitis based on the axial relationship of medication intake and systemic diseases. 
Furthermore, stepwise logistic analyses in disease severity were performed to discern the 
possible severity-dependent association between systemic diseases and the inflammatory 
burden augmented in severe periodontitis.  
The results of the current investigation demonstrated that medications for cardiovascular 
diseases (including calcium channel blockers and diuretics), diabetes (insulin and 
hypoglycemics) and antidepressant/antipsychotic drugs were positively associated with 
periodontitis after adjusting for age, gender, and the number of remaining teeth. On the 
contrary, anticoagulants, lipid-lowering medication, and bronchodilators were negatively 
associated with periodontitis after adjustment for all the confounding factors. Moreover, oral 
 
 
This article is protected by copyright. All rights reserved. 
hypoglycemics, calcium channel blockers and anticonvulsants demonstrated a severity-
dependent relationship, in which the frequency of intake correlated with periodontal disease 
severity after the adjustment for confounders.  
The most common medication unveiling in the current study was ACE inhibitors for the 
treatment of hypertension and congestive heart failure by reducing the activity of the renin-
angiotensin-aldosterone system. ACE inhibitors are often the first drug of choice for 
hypertension, particularly when diabetes is present as a comorbidity. Oxidative stress and 
endothelial dysfunction have been hypothesized to be involved in the pathogenesis of 
hypertension13, which share the common risk factors in chronic inflammation localized in 
periodontal tissues14. Although a number of cross-sectional studies15-17 documented an 
association between hypertension and periodontitis, in the present study, no significant 
association was found between ACE inhibitor consumption and periodontitis after adjusting 
for confounding factors. This result may be explained by the multiple pharmacological effects 
of ACE inhibitors throughout the broad spectrum of cardiovascular diseases and that ACE 
inhibitors are often used in combination with other antihypertensive drugs, especially thiazide 
diuretics18.  
Calcium channel blockers (CCB) are used in the management of cardiovascular conditions, 
including angina pectoris, cardiomyopathy, cardiac arrhythmias and hypertension. It has 
been reported that CCB administration, especially nifedipine, diltiazem and verapamil was 
associated with gingival overgrowth, and rarely, amlodipine and felodipine, as well19. 
Amlodipine was the most common (75%) CCB found in the present study, which is often the 
primary choice in the elderly population. Since this study only recorded pocket depth without 
the measure of clinical attachment loss, the significant association cannot be ruled out from 
the influence of gingival enlargement. However, a significant disease severity-dependent 
relationship was found under the common side-effect of gingival hyperplasia, which may 
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underline the substantial association between periodontitis severity and atherosclerotic 
cardiovascular disease.  
Diuretics were associated with periodontitis with an adjusted odds ratio of 1.6. Almost three-
fourth of diuretics in the present study were thiazide-like diuretics (THZs). A recent meta-
analysis demonstrated that no class of medication was significantly better than THZs as a 
first-line antihypertensive therapy18. The potential impact of diuretics on the periodontium 
might be explained by reduced salivary flow and composition20, contributing towards the 
development of periodontal disease. In a cross-sectional study among older adults, severe 
periodontitis was linked to high blood pressure with an OR of 2.93. In addition, the 
association was stronger when restricted to those with hypertension or taking anti-
hypertensive medications (OR= 4.2)21. 
Insulin and oral hypoglycemics were reported with significantly higher prevalence in the 
periodontitis group after adjustment. More importantly, the prevalence of oral hypoglycemics 
correlated directly with increasing severity of periodontitis. Epidemiologic evidence 
demonstrated an increase in extent and severity of periodontitis in diabetic adults22, and 
susceptibility to periodontitis was increased by nearly 3-fold in individuals with diabetes23. 
DM was recognized as a risk factor affecting the rate of periodontitis progression in 
longitudinal studies24. Furthermore, DM was identified as a modifiable contributor to systemic 
inflammatory burden25. Hence, metabolic control of diabetes was incorporated by the 2017 
World Workshop as a grade modifier to estimate the risk of future disease progression26.  
Depression is the most common psychiatric diagnosis amongst the elderly27. Epidemiologic 
studies provide substantial evidence that chronic stress and depression are associated with 
increased morbidity and negative outcomes for many chronic diseases, including: 
cardiovascular diseases28, diabetes29 and periodontitis30. Chronic stress and depression may 
result in dysregulation of the immune system and behavioral changes (smoking, alcohol 
consumption, and neglect of care) which can influence susceptibility to pathogenic infection 
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and periodontal breakdown31. The 17.8% of those taking antidepressants in our study 
population was in-line with a large epidemiologic study conducted in 2013 that found 16.7 % 
of US adults reported filling ≥ 1 prescription for psychiatric drugs32. Consumption of 
antidepressants in the present study was positively associated with periodontitis after 
adjustment (OR= 1.48, p=0.03), which might be related to drug-induced xerostomia, as well 
as a potential bidirectional relationship between depression and periodontitis. A plausible 
mechanism for this relationship could involve dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis and behavioural changes33. It was noteworthy that half of the 
antidepressants reported in our study were selective serotonin reuptake inhibitor (SSRIs), 
which has gained more recognition recently as decreasing proinflammatory cytokine levels in 
chronic inflammatory diseases34, 35. However, evidence for a potential benefit as host-
modulating effect on periodontal disease in humans remains weak36. 
Risperidone was the most common antipsychotic drug found in the current investigation 
(37.5%), which is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and 
autistic irritability. It was followed by clozapine (10%), which was mainly used for those 
unresponsive to other antipsychotics in treating schizophrenia37. A number of studies pointed 
out a higher prevalence and severity of periodontal disease among patients with 
schizophrenia or other psychiatric disorders38-40 and this may be related to poor oral hygeine 
and smoking41. In addition, the majority of antipsychotic medications, such as risperidone, 
quetiapine and olanzapine induce xerostomia which can aggravate the onset of 
periodontitis42.  
A few observational studies linked epilepsy to the likelihood of periodontitis and tooth loss43; 
moreover, the frequency of refractory seizures was significantly associated with periodontitis 
severity and poor oral hygeine44. Gabapentin (Neurontin) accounted for almost half of the 
reported anticonvulsants (44.3%) in the current study, followed by valproic acid (8.2%) and 
diazepam (6.2%). One study showed twice the likelihood of having severe periodontitis due 
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to drug-related xerostomia after exposure to anticonvulsants due to altered wound healing 
and inability for proper dental care45. It has been widely documented that anticonvulsants 
can cause gingival hyperplasia46, 19; yet, the prevalence is significantly reduced for the new 
generation of anticonvulsants such as gabapentin47. 
Interestingly, the results demonstrated an inverse relationship between periodontitis and 
lipid-lowering medications, anticoagulants and bronchodilators after adjustment for 
confounders. Exposure to lipid-lowering agents was associated with 80% reduced odds of 
having severe periodontitis. Statins are used to decrease lipid levels by inhibiting 
hydroxymethylglutaryl-coenzyme-A reductase. Atorvastatin (Lipitor) was most commonly 
prescribed (54%), followed by simvastatin (28%) in the current study. The anti-inflammatory 
pleiotropic effect of statins includes positive modulation of the inflammatory cascade and 
anabolic effects on bone formation48, which were shown to potentially decrease periodontal 
tissue breakdown after topical application49. Our results were in concordance with previous 
clinical observations50. 
Aspirin is the most frequently used anticoagulant in our study and exhibited a 50% higher 
likelihood of consumption in the healthy group. Low-dose aspirin acting as an anti-
inflammatory agent has been hypothesized to have potential host-modulating effects for 
periodontitis management. However, the evidence remains inconclusive51, 52. 
Bronchodilators were previously reported to have an inverse association with periodontitis53. 
A recent study revealed an odds ratio of asthma for participant with severe periodontitis was 
0.44, and the evidence was even stronger when using asthma medication as the outcome54. 
These results were consistent with our observation that individuals taking bronchodilators 
had less chance of having moderate to severe periodontitis. Mixed results with no or positive 
association were reported55, which warrant further research to assess the relationship 
between oral microbes, periodontitis and asthma. 
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The first limitation of the current retrospective study was that common confounding factors 
such as smoking and alcohol consumption were not included due to the incomplete data 
available in the EHR system. Secondly, pocket depth was chosen in the current study as the 
disease determinant which might not completely reflect the true disease severity. Finally, 
drug-drug interactions, which can produce additive, synergistic, or antagonistic 
pharmacological responses and alteration of host defense mechanisms was not included in 
the current analysis. The target population of the present study was an elderly group (mean 
age of 60.8 years) with generalized moderate to severe periodontal disease. Multiple factors, 
such as dry mouth, poor oral hygiene, inadequate access to dental care and decreased 
motor function may contribute to periodontal disease pathogenesis in this population. Given 
the wide range of the treatment regimens and the presence of multiple comorbidities, this 
study yielded an indirect implication for the association between periodontitis and multiple 




Overall, there was a significantly higher frequency of medication intake related to 
cardiovascular disease and diabetes in patients with periodontitis. A disease severity-
dependent relationship with medication consumption was found. This study provides indirect 
evidence for the possible relationship between systemic diseases and periodontitis. 
Footnotes 
† AXium, Henry Schein Inc., Melville, NY, USA  
‡ IBM SPSS Statistics for Mac, version 25.0, Armonk, NY, IBM Corp 
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* 208 85/123 61.2 ± 9.5 21.9 ± 5.5
GSP † 149 39/110 61.1 ± 9.8 22.2 ± 5.4
Remaining teeth (range)
Periodontitis 608 225/383 (37%/63%) 61.8 ± 9.8 (40-90) 22.7 ± 5.2 (6-32)
Table 1. Demographics of the study populations
Age and remaining teeth was presented with mean ± standard deviation (range)
*
 GMP represents "Generalized moderate periodontitis", 
† 
GSP represents "Generalized severe periodontitis"
Healthy 613  226/387 (37%/63%) 59.8 ± 13.5 (40-95) 26.6 ± 2.7 (19-32)
Total 1221 451/770 (37%/63%) 60.8 ± 11.8 (40-95) 24.7 ± 4.5 (6-32)
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Table 2. The most common medications and their consumption profile in each group
Medication Overall Healthy Group Periodontitis Group Crude Odds Ratio p-value
ACE Inhibitors 17.9% 14.4% 21.5% 1.64 0.001
Antidepressants 17.8% 14.5% 21.1% 1.57 0.003
Lipid-lowering Medications 16.5% 26.1% 6.7% 0.21 <0.001
Anti-coagulants 16.4% 21.0% 11.7% 0.50 <0.001
Beta-Blockers 14.7% 14.7% 14.8% 1.01 0.95
Antacid Medications 14.3% 14.0% 14.5% 1.04 0.87
Oral Hypoglycemics 12.9% 8.0% 17.8% 2.49 <0.001
Calcium Channel Blockers 12.4% 8.0% 16.8% 2.32 <0.001
Diuretics 12.0% 9.0% 15.0% 1.79 0.001
Anticonvulsants 7.9% 6.4% 9.5% 1.55 0.04












Table 3. The adjusted odds ratio for the effects of 
medications between "periodontitis" case and "healthy" 
control groups       
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statistically significant difference 
as p < 0.05 
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* Adjusted for age stratified by every 10-year strata (reference category 40-49 y), gender 
(reference female), and remianing teeth number stratified by two groups (< 20, ≥ 20 teeth) 
 
† Adjusted for age, gender 
(reference female), and remaining 
teeth number             
 
 
 
 
 
 
 
